Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03494504 · ClinicalTrials.gov registry record · Phase 3
ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis
A Phase 3 study of Allergic Conjunctivitis, sponsored by Aldeyra Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 318
- Enrollment target
- 7
- Study locations
NCT03494504 is a Phase 3 study of Allergic Conjunctivitis that has completed, run by Aldeyra Therapeutics. The registered enrollment target is 318 participants, above the 119-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target (167% higher). The trial reports 7 study locations across 5 states.
The verdict
NCT03494504, a Phase 3 study of Allergic Conjunctivitis, has completed, sponsored by Aldeyra Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 318 participants
- Enrollment target
- 7
- Study locations
Study Summary
A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled, Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solutions in Subjects with Acute Allergic Conjunctivitis
Conditions Studied
Interventions
- DRUG Vehicle Ophthalmic Solution
- DRUG Reproxalap Ophthalmic Solution (0.25%)
- DRUG Reproxalap Ophthalmic Solution (0.5%)
Study Locations (7)
California
- Eye Site Sacramento - Sacramento
- East West Eye Institute - Torrance
Texas
- Eye Clinics of South Texas - San Antonio
- R & R Research, LLC - San Antonio
Arizona
- Cornea Consultants of Arizon - Phoenix
Maryland
- Seidenberg Protzko Eye Associates - Havre de Grace
Massachusetts
- Andover Eye Associates - Andover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 318 participants |
| Start Date | 2018-03-30 |
| Est. Completion | 2018-11-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03494504
The ClinicalTrials.gov registry entry for NCT03494504 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 318 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 119-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target (167% higher). The listed sponsor is Aldeyra Therapeutics, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Allergic Conjunctivitis appearing as the primary indexed condition, and to 3 interventions - of which Vehicle Ophthalmic Solution is the first listed.
NCT03494504 reports 7 study locations spanning 5 distinct geographic areas - top geographies include California, Texas, Arizona.
Frequently Asked Questions
What is clinical trial NCT03494504 about?
NCT03494504 is a clinical study titled "ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis". A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled, Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solutions in Subjects with Acute Allergic Conjunctivitis
What is the current status of trial NCT03494504?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 318 participants. The study started on 2018-03-30. Estimated completion is 2018-11-05.
What conditions does trial NCT03494504 study?
This clinical trial studies the following conditions: Allergic Conjunctivitis.
What interventions are being tested in trial NCT03494504?
The interventions under investigation include: Vehicle Ophthalmic Solution (DRUG), Reproxalap Ophthalmic Solution (0.25%) (DRUG), Reproxalap Ophthalmic Solution (0.5%) (DRUG).
Who is sponsoring clinical trial NCT03494504?
This trial is sponsored by Aldeyra Therapeutics, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03494504 being conducted?
This trial has 7 study locations across Arizona, California, Maryland, Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Conjunctivitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy
RECRUITING · Phase 3
-
Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis
COMPLETED · Phase 3
-
A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
COMPLETED · Phase 3
-
Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution
COMPLETED · Phase 3
-
An Evaluation of the Onset and Duration of Action of AKF-1 Ophthalmic Solution in Treating Acute Allergic Conjunctivitis
COMPLETED · Phase 3
-
Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.